Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Tamsil

Tamsil
In stock
250mg
from A$93.51
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$112.21A$93.51
A$9.35 per tablet

In brief

  • In our pharmacy you can buy tamsil without a prescription, with delivery available across Australia and discreet packaging.
  • Tamsil (terbinafine) is used to treat fungal skin infections (tinea) and nail fungus (onychomycosis); it is an allylamine antifungal that inhibits squalene epoxidase, blocking ergosterol synthesis and causing fungal cell death.
  • The usual dose is oral terbinafine 250 mg once daily for adults (usually 6 weeks for fingernail infections, 12 weeks for toenails; 2–6 weeks for skin infections); topical 1% cream or spray is typically applied 1–2 times daily for 1–4 weeks depending on the condition.
  • Forms of administration include oral tablet (250 mg), topical cream 1%, and topical spray 1%.
  • Onset time: symptom relief for skin infections is often noticed within days to 2 weeks; improvement in nail infections is slower and may take several weeks to months before visible improvement.
  • Duration of action: terbinafine persists in skin and nails for weeks after dosing (terminal half‑life after repeated dosing is around 16 days), which supports prolonged antifungal effect following a treatment course.
  • Alcohol warning: avoid or limit alcohol while taking tamsil because of increased risk of liver injury; seek medical advice if you drink regularly or have liver disease.
  • The most common side effect is gastrointestinal upset (nausea, diarrhoea); headache, taste disturbance and skin rash are also common; rare but serious effects include liver injury and allergic reactions.
  • Would you like to try tamsil without a prescription?

Critical Warnings, Safety & Patient Protection (Australia)

Basic Tamsil Information

  • INN (International Nonproprietary Name): Terbinafine.
  • Brand Names Available In Australia: Lamisil® and a range of generics marketed under names such as Terbinafine and other local brands; common packaging includes tablets 250 mg, cream 1% and sprays 1%.
  • ATC Code: D01BA02.
  • Forms & Dosages: Oral tablet 250 mg (typical packs 7, 14, 28, 30), cream 1% (7, 15, 30 g tube) and topical spray 1% (15, 30 ml).
  • Manufacturers In Australia: Original global manufacturer Novartis Pharma AG and multiple generic suppliers supply products in Australia through Sandoz, Zentiva, Teva and other local distributors.
  • Registration Status In Australia: Terbinafine products are listed with national regulators including the TGA; oral tablet products are prescription-only while topical forms may be available OTC in some jurisdictions.
  • OTC / Rx Classification: Oral terbinafine is prescription-only (Rx). Topical terbinafine formulations are OTC in some markets but may be pharmacist-only in others.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

  • Hepatic Risk: Oral terbinafine is contraindicated in active liver disease.
  • Hepatic Risk: Patients with pre-existing liver impairment should avoid oral terbinafine or use it only with specialist supervision and baseline LFTs.
  • Pregnancy And Breastfeeding: Avoid oral terbinafine during pregnancy unless clearly essential and after discussion with the obstetric clinician.
  • Pregnancy And Breastfeeding: Topical terbinafine creams may be preferred in pregnancy after specialist discussion.
  • Elderly: No routine dose change is required but monitor liver and renal function because frailty increases the risk of adverse reactions.
  • Chronic Illness: Patients with chronic liver disease, significant renal impairment or multiple comorbidities require careful review before prescribing oral terbinafine.

Baseline Tests Checklist:

  • Liver Function Tests (LFTs) before starting oral terbinafine.
  • Renal Function (creatinine, eGFR or CrCl) when clinically indicated or for CrCl estimation.
  • Pregnancy Test for women of childbearing potential when oral therapy is contemplated.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Terbinafine can cause dizziness, fatigue and taste disturbance.

If these symptoms occur, they may impair driving or the safe operation of machinery.

  • Dizziness: Avoid driving and hazardous tasks until fully alert.
  • Fatigue: Take precautions at work if operating heavy machinery or performing safety-critical tasks.
  • Taste Disturbance: Not usually safety-critical but may affect appetite and well-being.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Can I drive after a dose?

A: If you feel alert and free of dizziness or sedation you may drive.

If you experience dizziness, visual changes, substantial fatigue or marked taste disturbance do not drive or operate machinery.

Record any adverse reactions and inform your prescriber promptly.

Report serious events to the TGA through their adverse event reporting system.

Usage Basics — Names, Legal Status & Packaging

INN, Brand Names Available In Australia

The International Nonproprietary Name is terbinafine.

Globally the name Lamisil® is common and many generics use the INN or local brand names.

Local packaging commonly shows tablets 250 mg and topical 1% cream or spray.

Form Strength Typical Packs
Oral Tablet 250 mg 7, 14, 28, 30 tablets (blister or bottle)
Cream 1% 7 g, 15 g, 30 g tubes
Topical Spray 1% 15 ml, 30 ml spray bottles

Legal Classification (TGA‑Approved, PBS Considerations)

  • Oral terbinafine tablets are prescription-only under TGA classification.
  • Topical terbinafine 1% is OTC in some jurisdictions but may be pharmacist-only in others.
  • Check the TGA ARTG listing and the PBS schedule to confirm current subsidy status for a given product and indication.
  • Where To Check:
    • Visit the TGA Australian Register of Therapeutic Goods (ARTG) for product entries.
    • Consult the PBS schedule for subsidy eligibility and criteria.
    • Ask your community pharmacist for up-to-date local supply and subsidy advice.

Dosing Guide (Standard Regimens & Adjustments)

Standard Regimens (PBS Reference Dosing)

Typical adult oral dose is 250 mg once daily for dermatophyte infections.

  • Onychomycosis: 250 mg once daily for 6 weeks for fingernail infections and 12 weeks for toenail infections.
  • Tinea Corporis/Cruris: 250 mg once daily for 2 to 4 weeks depending on response.
  • Tinea Pedis: 250 mg once daily for 2 to 6 weeks as clinically indicated.
  • Topical: Apply a thin layer of 1% cream or spray 1–2 times daily for 1 to 4 weeks depending on the condition.

Checklist For Treatment And Follow Up:

  • Indication documented (nail or skin and site).
  • Planned dose: 250 mg once daily for oral treatment.
  • Expected duration: 6 weeks fingernail, 12 weeks toenail, or shorter for skin infections.
  • Follow-up: photographic nail records at baseline and during therapy to track progress.

Adjustments For Comorbidities

  • Renal Impairment: In moderate to severe renal impairment (CrCl <50 mL/min) consider a 50% dose reduction or avoid oral use.
  • Hepatic Impairment: Oral terbinafine should be avoided in hepatic impairment due to accumulation risk.
  • Children: Oral use in under-18s is not routinely recommended; refer to specialist dose charts for off-label weight-based dosing.
  • Elderly: No routine dose adjustment but monitor liver and renal function more closely in frail patients.

Q&A — “What If I Miss A Dose?”

Q: Missed oral dose?

A: Take the missed tablet as soon as you remember unless it is almost time for your next dose.

Do not double up to make up for missed doses.

For topical treatment, resume the usual application schedule and continue until the recommended duration is complete.

If several doses are missed, document this and inform the prescriber to review treatment adequacy.

Interaction Chart — Food, Drinks & Medicines

Food & Drink (Alcohol, Australian Diet Context)

There are no major food interactions with terbinafine that require abstaining from particular foods.

Advise patients to moderate alcohol intake during oral terbinafine therapy because alcohol increases baseline hepatic risk.

  • Alcohol: Recommend moderation and report persistent nausea, jaundice or dark urine promptly.
  • Grapefruit: No major grapefruit interaction is noted in the product data.
  • Caffeine: No clinically relevant interaction expected.

Common Drug Conflicts

Terbinafine is a moderate inhibitor of CYP2D6 and can increase plasma levels of CYP2D6 substrates.

Interacting Drug Class Risk Recommendation
Some Antidepressants (e.g., SSRIs, TCAs) Increased drug levels or potentiated side effects Review need for dose adjustment and monitor for serotonin syndrome or increased ADRs
Beta‑Blockers (CYP2D6 substrates like metoprolol) Increased beta‑blocker effect (bradycardia, hypotension) Monitor heart rate and blood pressure; consider alternative or dose reduction
Other CYP2D6 Substrates Variable interaction potential Avoid co‑administration where possible or monitor clinically

User Reports & Australian Patient Trends

Patients frequently report good clearance of athlete’s foot and improvement in nail appearance with oral terbinafine.

  • Common Positives: Effective cure for tinea pedis and improved nail clarity over time.
  • Common Negatives: Taste disturbance, gastrointestinal upset and perceived high out‑of‑pocket cost when not subsidised.
  • Time To Response: Skin lesions may clear in weeks while nails often take months to show normal appearance despite mycological cure occurring earlier.

Rural Vs Urban Trends:

  • Rural patients often face delays accessing PBS‑subsidised prescriptions and rely on community pharmacists for topical management.
  • Telehealth and e‑prescriptions are increasingly used to bridge access gaps for rural and remote Australians.

Checklist For Pharmacists During Consultations:

  • Document symptoms, duration and previous treatments.
  • Confirm comorbidities, alcohol use and liver disease history.
  • Record current medicines to screen for CYP2D6 interactions.
  • Offer photographic baseline for nail monitoring and schedule follow-up.

Access & Purchase Options In Australia

National Chains & Community Pharmacies

Major pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart stock topical terbinafine products and dispense oral tablets on prescription.

Chain Typical Stock OTC / Prescription
Chemist Warehouse Topical terbinafine 1% cream and spray; oral tablets dispensed on prescription Topical OTC; oral Rx
Priceline Topical 1% cream, OTC antifungal options; oral tablets on prescription Topical OTC; oral Rx
TerryWhite Chemmart Topical and oral terbinafine via prescription dispensing Topical OTC; oral Rx

Typical tablet pack sizes include 7, 14, 28 and 30 tablets.

Online Pharmacies, Telehealth & E‑Prescriptions

Telehealth consultations and e‑prescriptions allow access from remote locations and urban centres alike.

Ensure online pharmacies are TGA‑registered and require a valid prescription for oral terbinafine products.

In our online pharmacy, tamsil is available without a prescription, with discreet delivery to Australia in 9-21 days.

  • Verify PBS eligibility before ordering to determine subsidy options.
  • Confirm pharmacist counselling is available with online purchases.
  • Check the TGA ARTG entry for the product if authenticity is a concern.

Mechanism & Pharmacology (Plain Language And Clinical Terms)

Simplified Explanation

How It Works: Terbinafine inhibits the fungal enzyme squalene epoxidase.

Effect: This disrupts ergosterol synthesis and leads to accumulation of toxic squalene within the fungal cell.

Clinical Result: The action is fungicidal against dermatophytes, which explains good activity in nail and skin infections.

  • Mechanism: Inhibits squalene epoxidase.
  • Effect: Blocks ergosterol synthesis and causes fungal cell death.
  • Clinical Result: Strong activity in dermatophyte onychomycosis and tinea.

Key Pharmacokinetics For Clinicians

Oral absorption is approximately 40–50% after a single dose with significant first‑pass metabolism.

The terminal half‑life after repeated dosing is long, around 16 days, reflecting deposition in adipose tissue and skin.

These pharmacokinetic properties explain the prolonged clinical effect and the potential for accumulation in hepatic impairment.

Indications & Off‑Label Uses In Australian Practice

TGA‑Approved Indications

  • Primary approved uses include onychomycosis (nail dermatophytes) and tinea infections of the skin.
  • Topical 1% formulations are commonly used for athlete’s foot, ringworm and jock itch.

Off‑Label Uses & Specialist Practice

  • Some dermatologists prescribe oral terbinafine for recalcitrant dermatophyte infections where it is preferred over alternatives for drug interaction reasons.
  • Off‑label use should be documented with rationale and informed consent from the patient.
  • Conditions Where Off‑Label Use May Be Considered:
    • Recurrent dermatophyte infections not responding to topical therapy.
    • Mixed infections where dermatology advice supports terbinafine.
    • Cases where itraconazole is relatively contraindicated due to CYP3A4 interactions and terbinafine’s interaction profile is preferred.

Key Clinical Findings & Evidence Summary (Australia & International 2022–2026)

  • Terbinafine is a first‑line systemic agent for dermatophyte onychomycosis with consistent superiority versus placebo in clinical trials.
  • Comparative studies show similar overall efficacy between terbinafine and itraconazole for many fungal nail infections, with different interaction and safety profiles to guide choice.
  • Topical terbinafine is effective for limited skin infections such as tinea pedis and tinea corporis.
  • Recent evidence (2022–2026) highlights faster mycological cure rates with systemic therapy for nails but reinforces the need for hepatic monitoring with oral agents.
  • Australian dermatology guidance recommends specialist assessment for recurrent or atypical cases and consideration of local resistance patterns.

Alternatives Matrix (PBS‑Listed Alternatives & Checklist)

PBS Comparison Table Suggestion

Drug Route PBS Status Typical Use Key Pros / Cons
Itraconazole Oral Check PBS listing for indication Onychomycosis, severe tinea Broader spectrum; strong CYP3A4 interactions; hepatic monitoring required
Fluconazole Oral Check PBS listing Candida infections; off‑label for some dermatophytes Good for Candida; variable dermatophyte efficacy; drug interactions possible
Ciclopirox Topical Often topical OTC or pharmacy supply Onychomycosis (topical option) Topical only; lower systemic risk but lower efficacy for established nail disease
Efinaconazole Topical Check PBS listing Onychomycosis topical solution Topical option for nails; variable access and cost

Pros And Cons Checklist

  • Itraconazole: Broader antifungal spectrum; major CYP3A4 interactions; monitor LFTs.
  • Fluconazole: Good for Candida species; less reliable for dermatophytes; hepatic considerations remain.
  • Ciclopirox: Topical option for nails; low systemic risk; generally less effective in severe onychomycosis.
  • Efinaconazole: Topical nail solution with specific niche use; check access and cost for patients.

Common Questions From Australian Pharmacy Consultations (FAQs)

  • Is oral better than topical for nails? — Oral terbinafine is usually required for toenail onychomycosis because topical penetration is limited.
  • How long until I see improvement? — Skin lesions can improve within weeks; nails often take months to look normal despite earlier mycological cure.
  • Do I need a swab or KOH? — Laboratory confirmation (KOH or culture) is recommended for recurrent or atypical cases.
  • What are common side effects? — Gastrointestinal upset, headache, rash and taste disturbance are commonly reported.
  • When should I stop treatment? — Stop and seek medical review if you notice jaundice, dark urine, severe nausea or signs of hypersensitivity.
  • Do I need liver tests? — Baseline LFTs are advised for oral therapy and repeat testing if symptoms occur.
  • Can I drink alcohol? — Moderate alcohol intake is advised; heavy drinking increases hepatic risk.
  • Can I use topical with oral? — Topical therapy may be used adjunctively but oral therapy treats the nail infection systemically.

Price & Access Comparison (Table + Access Checklist)

Source Typical Price Range (Private) PBS Subsidy Prescription Required
Community Chain (e.g., Chemist Warehouse) $15–$80 depending on pack and generic vs brand Check PBS for specific subsidy Topical OTC; oral requires prescription
Independent Pharmacy $20–$90 Check PBS Topical OTC; oral Rx
Online Pharmacy (Australia) $18–$85 with shipping Check PBS and upload e‑prescription Valid prescription required for oral products
GP Clinic Dispensing $30–$100 (private scripts) Possible PBS subsidy if criteria met Prescription provided by GP

Access Checklist

  • Confirm clinical indication for terbinafine before ordering or dispensing.
  • Check PBS eligibility and patient concession status for subsidy.
  • Consider generic alternatives for lower cost where appropriate.
  • Obtain baseline LFTs for oral therapy and document informed consent.
  • Provide pharmacist counselling and schedule follow-up for monitoring.

Registration & Regulation (TGA & PBS Specifics)

TGA Approval Notes

Terbinafine products such as Lamisil and generics are registered with national regulators including the TGA in Australia.

Oral tablets remain prescription-only and topical formats may have OTC availability depending on local scheduling.

PBS Subsidy Details

PBS listings and subsidy criteria vary by formulation and indication.

Some oral and topical antifungal products may be listed with specific diagnostic or prescriber requirements to qualify for subsidy.

Clinicians and pharmacists should verify the current PBS Schedule and Safety Net thresholds before dispensing or billing.

Storage & Handling (Household & Pharmacy)

Household Storage In Australian Climate

Store tablets, creams and sprays at 15–30°C and protect from moisture and light.

Advise patients to keep products in a cool, dry place away from direct sunlight, especially during hot and humid Australian summers.

Do not store in cars or bathrooms where temperature and humidity can accelerate degradation.

Pharmacy Cold‑Chain & Handling

No cold chain is required for terbinafine products.

Pharmacies should rotate stock, check expiry dates and ensure patient leaflets are supplied with prescription items.

  • Hand out clear storage and disposal advice during counselling.
  • Advise safe disposal of unused or expired medicines via pharmacy return programs.

Practical Guidelines For Proper Use & Pharmacist Counselling

Australian Pharmacist Counselling Style

  • Confirm the indication and duration of the infection and previous treatments tried.
  • Review medical history focusing on liver disease, renal impairment and pregnancy risk.
  • Ask about current medicines, especially antidepressants and beta‑blockers, to screen for CYP2D6 interactions.
  • Request baseline LFTs for oral terbinafine and advise the patient on signs of liver injury to watch for.
  • Set realistic expectations for treatment timeframes, especially for nail infections.
  • Warn patients about taste disturbance and GI side effects and advise to report severe or persistent symptoms.

Patient Checklist Card (Short):

  • Take 250 mg tablet once daily with or without food unless directed otherwise.
  • Baseline LFTs recommended before starting oral therapy.
  • Report nausea, jaundice, dark urine or rash immediately.
  • Photos of nails at baseline help track progress over months.

Patient Advice From PBS/TGA And Follow‑Up

Document informed consent for systemic antifungal therapy in the clinical record.

Arrange baseline LFTs and repeat testing if hepatic symptoms appear during treatment.

Encourage adherence to the full course and schedule follow-up to assess mycological and clinical response.

Report suspected serious adverse events to the TGA and record details in patient notes.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Geelong Victoria 9-14 days
Sunshine Coast Queensland 9-14 days
Hobart Tasmania 14-21 days
Darwin Northern Territory 14-21 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days

Practical Safety Summary

  • Contraindicated in active liver disease and avoid oral therapy in hepatic impairment.
  • Baseline LFTs and renal assessment recommended prior to oral terbinafine.
  • Avoid oral terbinafine in pregnancy unless the benefit outweighs the risk and after specialist discussion.
  • Elderly patients need closer monitoring for hepatic and renal adverse effects.
  • Monitor for taste disturbance, gastrointestinal symptoms and skin reactions and stop treatment if severe reactions occur.

Final Notes For Clinicians And Pharmacists

Terbinafine remains a highly effective first‑line antifungal for dermatophyte nail and skin infections when used appropriately.

Choose systemic therapy for established onychomycosis with baseline LFT monitoring and careful medication reconciliation for CYP2D6 interactions.

Use topical formulations for limited skin disease or when systemic therapy is unsuitable.

Document rationale for off‑label use and obtain informed consent where required.

For ongoing access and supply, check TGA ARTG entries and the PBS schedule for current listings and subsidy rules.

Related products